OncoMed Announces Multiple Abstracts Related to Anti-TIGIT Program Accepted for Presentation at the American Association for Cancer Research Annual Meeting 2017
02 mars 2017 08h30 HE
|
OncoMed Pharmaceuticals, Inc.
REDWOOD CITY, Calif., March 02, 2017 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals Inc. (NASDAQ:OMED) will present new data related to its clinical and preclinical immuno-oncology and anti-cancer stem...
OncoMed Pharmaceuticals to Report Fourth Quarter and Year End Financial Results on March 8, 2017
01 mars 2017 16h30 HE
|
OncoMed Pharmaceuticals, Inc.
REDWOOD CITY, Calif., March 01, 2017 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (Nasdaq:OMED), a clinical-stage biopharmaceutical company focused on discovering and developing novel...
OncoMed Enrolls First Patient in Phase 1b Clinical Trial of its Anti-DLL4/VEGF Bispecific Antibody in Patients with Platinum-Resistant Ovarian Cancer
13 févr. 2017 08h30 HE
|
OncoMed Pharmaceuticals, Inc.
REDWOOD CITY, Calif., Feb. 13, 2017 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED), a clinical-stage company focused on discovering and developing novel anti-cancer stem cell and...
OncoMed Pharmaceuticals to Present at the BIO CEO and Investor and Leerink Global Healthcare Conferences
08 févr. 2017 16h30 HE
|
OncoMed Pharmaceuticals, Inc.
REDWOOD CITY, Calif., Feb. 08, 2017 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED), a biopharmaceutical company focused on discovering and developing novel anti-cancer stem cell and...
OncoMed Initiates Enrollment of Phase 1b Clinical Trial of Brontictuzumab for the Treatment of Metastatic Colorectal Cancer Patients
20 janv. 2017 08h30 HE
|
OncoMed Pharmaceuticals, Inc.
REDWOOD CITY, Calif., Jan. 20, 2017 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED), a clinical-stage company focused on discovering and developing novel anti-cancer stem cell and...
OncoMed Announces Year-End Cash Balance and 2017 Outlook
05 janv. 2017 08h30 HE
|
OncoMed Pharmaceuticals, Inc.
Enters 2017 with $184.6 Million in Cash Potential for Five Program Opt-ins Totaling Over $170M Anti-TIGIT (I/O#2) IND Filed REDWOOD CITY, Calif., Jan. 05, 2017 (GLOBE NEWSWIRE) -- OncoMed...
OncoMed Initiates Enrollment of Phase 1b Clinical Trial of Anti-DLL4/VEGF Bispecific Antibody as Second-line Treatment for Metastatic Colorectal Cancer Patients
04 janv. 2017 08h30 HE
|
OncoMed Pharmaceuticals, Inc.
REDWOOD CITY, Calif., Jan. 04, 2017 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED), a clinical-stage company focused on discovering and developing novel anti-cancer stem cell and...
OncoMed Announces Departure of Chief Medical Officer
05 déc. 2016 08h30 HE
|
OncoMed Pharmaceuticals, Inc.
REDWOOD CITY, Calif. , Dec. 05, 2016 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED), a clinical-stage company focused on discovering and developing novel anti-cancer stem cell...
OncoMed Presents Initial First-in-Human Data for Anti-DLL4/VEGF Bispecific and Anti-RSPO3 at the 28th EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics Symposium
29 nov. 2016 08h30 HE
|
OncoMed Pharmaceuticals, Inc.
Partial Responses and Stable Disease Achieved with Bispecific as a Single-Agent Safety and Target Engagement Established for Anti-RSPO3 REDWOOD CITY, Calif., Nov. 29, 2016 (GLOBE NEWSWIRE) --...
OncoMed Pharmaceuticals to Present at the 28th Annual Piper Jaffray Healthcare Conference
22 nov. 2016 08h30 HE
|
OncoMed Pharmaceuticals, Inc.
REDWOOD CITY, Calif., Nov. 22, 2016 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED), a biopharmaceutical company focused on discovering and developing novel anti-cancer stem cell...